Each year, three faculty members receive Mizzou Law awards for their outstanding work: one for a scholarly work, one for teaching, and one for the administration of justice. The Husch Blackwell Distinguished Faculty Achievement Award is awarded for teaching excellence, and the recipient is chosen by the Missouri Law Review’s editorial board. This years’ awardee is Professor S. David Mitchell.…
Category: Prof. Erika Lietzan ⋅ Page 1
Professor Lietzan Speaks at Food & Drug Law Institute Annual Meeting
Last week, Professor Erika Lietzan spoke at the Food & Drug Law Institute’s annual meeting. Her talk discussed the Fifth Circuit’s Apter v. HHS decision (which relates to FDA’s famous “you’re not a horse” tweet.) The FDLI is a nonprofit membership organization for specialists in food and drug law, whether they are in private practice, industry, government, or academia. Professor…
Professor Lietzen Fall 2023 Scholarship Recap
In September, Professor Erika Lietzen presented a work in progress at BYU’s law school. The presentation was called “Accountability By Petition.” She will be submitting the paper – now called “The Power of Petitions” – in the February cycle. The paper explores the role that petitions to federal agencies can play in helping us hold agencies accountable, and it is…
Prof. Lietzan named to Best Lawyers List
For the 10th straight year, Erika Lietzan, William H. Pittman Professor of Law & Timothy J. Heinsz Professor of Law at Mizzou Law, was named a Best Lawyer in FDA Law and for the 16th straight year as a Best Lawyer in Biotechnology & Life Sciences Law for…
Are Drug Companies the Villain?
For years, brand drug companies have been villainized for “evergreening” or manipulating the law to extend the period of exclusivity for drugs beyond their 20-year patent — a practice critics say unfairly prevents competition from generic drug companies and that has prompted legislators to consider significant reform to policies that govern the pharmaceutical industry. But an audit of more than…
Prof. Lietzan publishes new paper on why medical device companies rarely renew patents
Professor Erika Lietzan, the William H. Pittman Professor of Law and Timothy J. Heinsz Professor of Law at Mizzou Law, recent published a new paper, “The Case of the Missing Device Patents, or: Why Device Patents Matter,” in the Fordham Intellectual Property, Media & Entertainment Law Journal. To read Prof. Lietzen’s article, visit:…
Prof. Erika Lietzan Re-appointed to ACUS, Named to Best Lawyer in America List
Erika Lietzan, the William H. Pittman Professor of Law & Timothy J. Heinsz Professor of Law was recently re-appointed to a two-year term as a public members of the Administrative Conference of the United States (ACUS). ACUS is an independent federal agency dedicated to improving the administrative process through consensus-driven applied research and providing nonpartisan expert advice and recommendations for…
Prof. Lietzen named Best Lawyer in America in FDA and Biotechnology & Life Sciences Law
Professor Erika Lietzan has again been named a “Best Lawyer in America” in both FDA Law and Biotechnology & Life Sciences. This marks the eighth year in a row for FDA Law and the fourteenth year in a row for Biotechnology Law. The Best Lawyers honor is meant to identify the top 5 percent of attorneys in the United States,…
Professor Lietzan elected as a member of the CREDIMI
Professor Erika Lietzan is a “Membre Associé” at the Centre de Recherche sur le Droit Des Marchés et des Investissements Internationaux (CREDIMI), which is part of the Faculty of Laws, Economics, and Politics of Dijon, within the University of Bourgogne in Dijon, France. The CREDIMI focuses on the study of the market, its functioning, and its players, including specific sectoral…
Professor Lietzan Appointed to Food and Drug Law Leadership Positions
Professor Erika Lietzan has been appointed co-chair of the annual conference of the Food and Drug Law Institute (FDLI). FDLI is a non-profit organization focused on food and drug law, supported by members from FDA, the food and drug bar, lawyers and regulatory specialists within the regulated industries, and academics specializing in FDA law. She has been a member of…